Tenax Therapeutics (TENX) Capital Expenditures (2010 - 2023)

Tenax Therapeutics (TENX) has 14 years of Capital Expenditures data on file, last reported at $1602.0 in Q2 2023.

• For the quarter ending Q2 2023, Capital Expenditures changed N/A year-over-year to $1602.0; the trailing twelve-month figure through Jun 2023 stood at -$1157.0 (down 111.93% YoY), and the FY2022 full-year result was $2323.0, down 55.77% from the prior year.
• Capital Expenditures rose to $1602.0 in Q2 2023, from $1241.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6323.0 in Q1 2022 to a low of -$4000.0 in Q4 2022.
• A 5-year average of $1942.4 and a median of $1698.0 in 2021 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures rose 15.1% in 2019 and sank 335.57% in 2022, its largest moves.
• Tracing TENX's Capital Expenditures over 5 years: stood at $3574.0 in 2019, then declined by 2.35% to $3490.0 in 2020, then tumbled by 51.35% to $1698.0 in 2021, then slumped by 335.57% to -$4000.0 in 2022, then jumped by 140.05% to $1602.0 in 2023.
• Business Quant data shows TENX's Capital Expenditures at $1602.0 in Q2 2023, $1241.0 in Q1 2023, and -$4000.0 in Q4 2022.